Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2013 Jul 17;1:39. doi: 10.1186/2051-5960-1-39

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2013 Pan and Dobrowsky; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Inhibition of Erb B2 with erlotinib suppressed diabetes-induced p42/p44 MAPK pathway activation in sural nerves. (A): Sural nerves were isolated from vehicle or erlotinib-treated control and diabetic mice (n = 3–4 per group) at week 21. Protein lysates were prepared and erbin levels and p42/p44 MAPK (pErk) levels were determined by immunoblot. (B): Quantification demonstrated a significant decrease of erbin and an increase in p42/p44 MAPK activation in vehicle-treated diabetic mice. Erlotinib treatment suppressed p42/p44 MAPK activation in erlotinib-treated diabetic mice (*, p < 0.05; **, p < 0.01).